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1. Introduction 
Overuse of antimicrobial agents in human and veterinary medicine is a serious problem 
worldwide. Bacteria have developed resistance mechanisms decades ago, even before wide 
application of antibiotics had started. Naturally they had learned to cope with an 
unfavourable environment well before man changed it. Bacteria can develop resistance 
utilizing different mechanisms. Through mobile genetic elements bacteria transfer resistance 
to progeny, raising concerns about not being able to control the infection (Velhner et al., 
2011). An understanding of resistance mechanisms is essential for developing new 
therapeutics and overcoming current problems in therapy.  
Single point mutations in target genes is sufficient to develop resistance (Giraud et al., 1999).  
Quinolones are directed to the complex of DNA and the enzyme Gyrase A and/or 
topoisomerase IV. They disturb replication of bacteria by changing the topology of DNA. 
Mutations in genes coding these important enzymes enable bacteria to develop resistance, 
creating a favourable environment for their survival. Gyrase A consists of two subunits 
encoded by genes gyrA and gyrB. In the gyrA gene, there is a quinolone resistance-
determining region (QRDR) where mutations occur, if bacteria are exposed to antimicrobials 
(rev. by Velhner et al., 2010). The QRDR extends from codon 67 to 106, but upon quinolone 
treatment, mutations mostly occur on codons 83 and 87 (Yoshida et al., 1990). In the gyrB 
gene, the QRDR region extends from codons 426 to 447 in E. coli and also in Salmonella 
(Yoshida et al., 1991). Gyrase A is a target enzyme in gram negative bacteria. Topoisomerase 
IV is a target enzyme for gram positive and a secondary target in gram negative bacteria. 
Topoisomerase IV is encoded by two genes termed parC and parE. In environments where 
antimicrobials are persistently in use, multiple resistances develop and genes for both 
enzymes can be mutated. To monitor the level of resistance it is important to estimate 
minimal inhibitory concentration (MIC) for certain antibiotics since this would tell us what 
the risk of antimicrobial use is and whether to expect mutations on target genes.  
The focus of the present review will be on resistance development in bacteria that cause 
food-borne illness and are most often found in livestock industry. Three genera have been 
selected because of their significance in both human and veterinary medicine: Salmonella 
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spp., Escherichia coli and Campylobacter spp. These bacteria are transferred to humans 
through the food chain and tend to persist in farms, alimentary and medical settings. 
Salmonellae are very invasive and spread very quickly from animal to animal. The rate of 
Salmonella Enteritidis isolation in groups of chickens infected orally with 102 cfu/0.1 ml 
(group A), the sentinels (group C) and group of chickens infected orally with 104 cfu/0.1ml 
and sentinels (group D) is presented in Fig 1. The low infective doses did not prevent 
horizontal spread of SE to contact chickens during 14 days post infection. Salmonella 
Enteritidis could be isolated in highest percent (group C and D) from birds exposed by 
contact (Velhner et al., 2005). If chickens are infected during the growth Salmonella will be 
transmitted in slaughterhouses, contaminating food. Escherichia coli are widely distributed 
among farm animals. Pathogenic isolates but also commensals, tend to harbour different 
resistance mechanisms. Genetic polymorphism in target genes is noted in quinolone 
resistant strains. However, just recently identical extended-spectrum -lactamase genes 
were found among E. coli isolates from humans and retail chicken meat in The Netherlands. 
This implicates spread of E. coli to people through the food chain, raising concern about 
prudent use of antimicrobial agents in farm animals. To minimize health problems in 
humans caused by infection with food borne bacteria, it is also important to develop strict 
measures to prevent contamination during food processing and handling (Overdevest et al., 
2011). Campylobacter species gain resistance to quinolones easily and as such present a risk 
for consumer’s safety. Usually they are not pathogenic for animals, but if humans are 
infected through food this can cause gastrointestinal diseases. Resistance to quinolones is of 
special concern because proper medical treatment could be difficult if patients are infected 
with multiple resistant microorganism. Children, elderly people and immunocompromised 
patients are at highest risk in such situation. Monitoring of antimicrobial resistance is 
therefore necessary and in most countries is introduced as a part of the national programs in 
human and veterinary medicine.  
 
Fig. 1. Incidence of salmonella isolation from cloacal swabs during the experiment. Groups 
C and D are sentinel chickens. 
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2. Point mutations in topoisomerase genes of Salmonella 
There are over 2000 serotypes of the genus Salmonella and most of them are pathogens for 
humans. They are usually transmitted by food of animal origin and animal products. 
Salmonellae are invasive, tend to spread clonally and also gain multiple resistance 
phenotypes. There is a number of papers dealing with the resistance mechanisms to 
quinolones in Salmonella. Every decade is marked with the predominance of certain 
serotypes and distinctive resistance patterns. Most frequently quinolones will induce the 
apparition of point mutations in the gyrA gene but there are reports on mutations in other 
topoisomerase genes. If bacteria are highly resistant to fluoroquinolones (FQ) and MIC 
exceeds the clinical breakpoint, a double mutant can be expected. Nevertheless in quinolone 
resistant Salmonella, the most frequent mutations are on the gyrA gene, while mutations in 
multiple loci are reported occasionally. We will summarize recent reports concerning 
mutations in topoisomerase genes and present our current opinion about resistance 
mechanisms.  
Giraud et al. (1999) proposed that in veterinary isolates the most common amino acid 
substitution in gyrA gene is Ser83Phe, because of wide application in animal husbandry of 
enrofloxacin, a fluorinated quinolone derivate. A similar result was obtained by 
spontaneous mutant selection with nalidixic acid (NAL), ciprofloxacin (CIP) and 
enrofloxacin (ENR). Enrofloxacin selects mutants with Ser83Phe substitution on gyrA, 
while NAL and CIP favour substitutions on codon 87 (Levy et al., 2004). Therefore 
mutations on topoisomerase genes depend on antimicrobial agents to which Salmonella are 
exposed (Giraud et al., 2006). In a collection of isolates from farm animals in England and 
Wales, mutation at codon Ser83 induced higher MIC to ciprofloxacin compared to mutations 
at Asp87 (Liebana et al., 2002). Mutational polymorphism is prominent in topoisomerase 
genes in Salmonella and sometimes depends on serotype, country of origin or continent 
(Escribano et al., 2004; Hopkins et al., 2005; Lindstedt et al., 2004; Piddock et al., 1998; San 
Martin et al., 2005). The most frequent are mutations on gyrA, Ser83Tyr, Phe or Ala and on 
codon Asp87Asn, Gly, Tyr or Lys, (Giraud et al., 2006; Hopkins et al., 2005; Lee et al., 
2004). In one clinical isolate of Salmonella Enteritidis described in the research work of 
Lindstedt et al. (2004), a novel mutation was found on gyrA at Gly81His. This mutation 
coupled with Ser83Tyr exchange, increased the MIC to CIP to 8 g/ml (doubled in 
comparison to single mutant). Mutations on Gly81Ser do not cause resistance to quinolone 
and FQ in Salmonella Typhimurium when spontaneous mutants are induced in vitro. The 
substitution to serine is too weak to induce resistance to FQ (Reyna et al., 1995). In another 
experiment Gly81Cys in vitro mutants induced significant increase in MIC to NAL and 
CIP compared to the parent strain (Giraud et al., 2003). Novel mutants were found in clinical 
Salmonella isolates from patients that were hospitalized because of enteric infection in 
Tehran, Iran. These novel mutations on gyrA are: Ala118Thr, Ser111Thr, Arg47Ser, 
Leu41Pro, Asp147Gly and Gly133Glu coupled with mutations either on 83 or 87. The 
significance of these novel substitutions is not known (Hamidian et al., 2011). Sallmonella 
gain resistance to FQ during the therapy. In two immunocompromised patients, Salmonella 
Enteritidis and Salmonella Typhimuirum susceptible to FQ were isolated. After the therapy 
with norfloxacin (patient 1) and cefotaxime (patient 2), the resistant mutants (Ser83Tyr, 
Ser83Phe) were found when the treatment was completed. In vivo mutant and pre-therapy  
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isolates were of the same clone, supporting the opinion that quinolone selection can occur in 
vivo during antibiotic treatment (Ouabdesselam et al., 1996). The role of mutation of gyrB to 
yield quinolone resistance was studied by Gensberg et al. (1995). The authors found a novel 
mutation on gyrB at codon Ser463Tyr, located outside the QRDR. Complementation 
experiment with the E. coli carrying plasmid pBP548, having the wild type GyraseB, have 
shown that one isolate, termed L18, regains a susceptible phenotype to quinolones. The 
mutated region in L18 did not change the hydrophobicity of the enzyme but possibly 
introduced a conformational change in the molecule. Heisig (1993) and Heisig et al. (1995) 
reported that in the early 1990's, a Salmonella Thyphimuirum var. Copenhagen multiple 
resistant clonally spread from cattle to humans. These isolates had two point mutations on 
gyrA Ser83Ala and Asp87Asn or Tyr. Complementation experiments have provided the 
evidence that target gene gyrA, if mutated, plays a role in resistance to fluoroquinolones and 
that also gyrB is implicated in resistance development. Guerra et al. (2003) found three point 
mutations in two Salmonella Typhimurium var. Copenhagen from the early 1990 that were 
sent to National Salmonella Reference Laboratory in Germany. The mutations were found 
on codon Ser83 Ala and on codon Asp87Asn in gyrA. A novel mutation was found on 
gyrB at codon Ser464Phe and one additional mutation was found on QRDR of parC 
(Ser80Ile). Casin et al. (2003) reported that high level resistance to ciprofloxacin was found 
in two patients (74 year old man, isolate STmA and 3 years old boy, isolate STmB) and that 5 
strains had the same point mutations on gyrA (Ser83Phe and Asp87Asn), while on gyrB 
mutation was found at Ser464Phe. In STmA, a mutation was found on parC (Glu84Lys) 
while in an isolate from a 3 year old boy, the mutation was Ser80Arg. The two isolates 
were not clonally related. The isolate STmA could acquire resistance during treatment with 
ciprofloxacin, although it is still hard to explain why the isolate STmB from the boy was 
floroquinolone resistant and yet the patient had never been exposed to ciprofloxacin. It is 
possible that both Salmonellas appeared independently from the environment, suggesting 
the presence of multiple resistant ST in communities in France. A comprehensive research 
on mutational polymorphism in Salmonella enterica in the United Kingdom is provided by 
Eaves et al., 2004. In this strain collection among 182 isolates, five had a novel substitution 
on gyrB. In Salmonella enterica serovar Seftenberg Tyr420 is mutated to Cys and in serovar 
Newport Arg at 437 was mutated to Leu. These mutations were also found in Salmonella 
Enteritidis and serovar Mbandaka. The authors stated that the mutations occur in close 
proximity to the quinolone binding pocket, most likely contributing to decreased binding of 
quinolones. The first report on parC mutations in Salmonella was provided by Ling et al. 
(2003). They discovered that a single point mutation in parC confers resistance to quinolones 
and the highest resistance level was obtained if double mutation occurs in Ser83 and Asp87 
on gyrA gene. Double mutants were common in clinical isolates reported in the research by 
Ling et al., 2003. Another interesting observation about parC mutations comes from Eaves et 
al. (2004) who found out that the parC mutations, single or coupled with gyrA mutation, in 
Salmonella induce lower geometric mean (GMM) and MIC50 comparing to single gyrA 
mutant, suggesting compensatory mechanism of parC point mutation at 57. This observation 
was not found by other authors or in E. coli, but there is evidence that Thr57Ser 
substitution in parC (CG transversion) does not induce quinolone resistance per se 
(Baucheron et al., 2005; Kim et al., 2011).  
High fluoroquinolone resistance in Salmonella is not very common and sometimes depends 
on serovar and the rate of exposition to antimicrobial agents. Heisig et al. (1995) stated that 
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clinical resistance to fluoroquinolones is rare due to the high antibacterial activity against 
Salmonella, because of the lack of enzymatic inactivation of the drug and because it is hard to 
transfer such resistance. Fluoroquinolone resistant Salmonella Typhimurium mutants 
selected in vitro and in vivo have shown a low fitness cost indicated by an impaired growth 
rate comparing to susceptible strains. However, if a compensatory mutation occurs, bacteria 
have more chance to survive in the presence of antibiotics. In survivors, the role of 
overexpressed multidrug pumps is also evident (Giraud et al., 2003). Indeed, most often 
high resistance to fluoroquinolone is coupled with multiple resistance phenotypes. If 
bacteria harbor resistance to ampicillin, chloramphenicol, sulfa drugs and fluoroquinolones 
the therapy of ill individuals that require treatment could be difficult. There is an opinion 
that in such cases different resistance mechanisms are involved in selecting mutants that are 
capable of surviving in the environment. Three major mechanisms are: mutation in 
topoisomerase II and IV, overexpression of efflux pump and decreased outer membrane 
permeability (Cloeckaert & Chaslus-Dancla, 2001; Giraud et al., 2006; Hopkins et al., 2005).  
In Spain, the rate of NAL resistant Salmonella isolated from humans increased during the 
year 1994 and peaked at 2001 to 46.2%. In 2003 NAL resistance was found in 38.5% isolates. 
Out of 164 non-typhoid Salmonella from food collected from 1999 to 2003, 124 isolates were 
NAL resistant. Point mutations were found dominantly at codon 87 and also codon 83. The 
first Salmonella isolate from humans resistant to CIP was reported in March 2003. 
Subsequently in the same year, 2 more CIP resistant isolates were found. Three Salmonella 
were isolated from children and two from patients aged 49 and 47. These strains possessed 
three point mutation in QRDR of the gyrA gene (aa substitution were at Ser83Phe and 
Asp87Asn) and additional mutation was found on parC at Ser80Arg (Marimon et al., 
2004). Similar increase in number of NAL resistant clinical isolates of Salmonella enterica was 
recorded in Korea. In 1996 NAL resistance was found in 1.8% isolates and by 2000-2002 it 
increased to 21.8%. Single mutation were at codon 87 (39 strains) and at codon 83 in 4 strains 
(Choi et al., 2005). An increase from 0.4% in 1996 to 2.3% in 2003 was also recorded for NAL 
resistant Salmonella enterica in the USA. In 14 CIP resistant isolates, double mutations were 
found at gyrA at 83 (Ser83Tyr or Ser83Phe) and on 87 (Asp87Gly or Asp87Asn). 
Mutations on gyrB, parC and parE were not detected (Stevenson et al., 2007). Salmonella 
Seftenberg isolated during a nosocomial outbreak in Florida were included in the study of 
Whichard et al. (2007). In these isolates point mutations were found on gyrA at Ser83Tyr 
and Asp87Gly and on parC (Ser80Ile and/or Thr57Ser) while MIC to CIP was 
>4g/ml. Most of the Salmonella Seftenberg isolates from their collection also contained 
mechanism of extended-spectrum cephalosporin resistance. Such co-resistance in Salmonella 
Seftenberg maybe plays a role in the epidemiology of Salmonella.  
If a high resistance to fluoroquinolone occurs, several point mutations are usually detected 
in target genes. In Salmonella collected in Hong Kong in the period from 1990 to 2001, highly 
resistant strains to fluoroquinolone were recorded. Two isolates harbour mutations at gyrA 
(Ser83Phe, Asp87Asn) and on parC at Ser80Arg. MIC to ciprofloxacine was 8-16 
g/ml for these isolates. In 4 additional isolates, point mutations were found on gyrA 
(Ser83Phe, Asp87Gly), in parC (Ser80Arg) and in parE, with a new substitution at 
Ser458Pro. In these Salmonella MIC for ciprofloxacin was even higher (16-32 g/ml). For 
the first time a mutation, Thr57Ser in parC, alone or coupled with gyrA mutation, was 
reported. Single parC mutant were less susceptible to CIP (MIC < 0.12 g/ml) suggesting 
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that such mutation is a marker of low level resistance to FQ (Ling et al., 2003). A first report 
of infection with fluoroquinolon resistant Salmonella in the USA was published by Olsen et 
al. in 2001. The infection occurred in nursing homes, where Salmonella enterica serotype 
Schwarzenground spread among residents in two distant facilities. The patient, who 
returned from the Philippines and was hospitalized in New York and afterwards resided in 
a nursery home, was most likely a vehicle for the transmission. In fact, after comprehensive 
epidemiological survey Salmonella Schwarzenground was found in two environmental 
samples taken from the mattress and door handle in the room of the ill resident. Twenty 
nine months Salmonella Schwarzenground was present in the environment and this infection 
lead to the death of 3 people in the nursing home. PFGE pattern was similar for all the 
strains and the same gyrA mutations were found during survey (Ser83Phe and 
Asp87Gly). MIC to ciprofloxacin was 4g/ml. The first report on clinical Salmonella 
Typhimurium DT12 highly resistant to fluoroquinolones in Japan comes from Nakaya et al. 
(2003). The STDT12 was isolated from a stool of an infant with diarrhoea. The isolate was 
resistant to ampicillin, streptomycin, gentamycin, tetracycline, chloramphenicol, 
sulfamethoxazole/trimetoprim, nalidixic acid and fluoroquinolones. It exhibited resistance 
also to levofloxacin (MIC 8 g/ml), ciprofloxacin (MIC 8 g/ml) and norfloxacin (MIC 16 
g/ml). Three point mutations were distributed on gyrA Ser83Phe and Asp87Asn and 
on parC, Ser80Arg. Therapy was successful with fosfomycin, a drug prescribed for babies 
and children. Salmonella isolated from cattle in Japan did not posses such resistance 
phenotype and could not be linked to this outbreak at the time being. However, in 2005, the 
spread of multiple resistant Salmonella enterica serovar Typhimurium DT104 was found in 
Japan (Izumiya et al., 2005). The isolates harboured mutations on gyrA gene Ser83Phe and 
Asp87Asn and on parC Ser80Arg was found. Besides the same point mutations, similar 
resistotypes were detected in human and nonhuman isolates in their study. Genetically 
related ciprofloxacin resistant Salmonella Typhimurium and Salmonella Choleraesuis were 
found in Taiwan in people and pigs. In human isolates MIC for ciprofloxacin was 8–64 
g/ml while in pig isolates MIC range from > 0.125 to 64 g/ml. In Salmonella 
Typhimurium from patients, mutations were found in gyrA (Ser83Phe and Asp87Gly) 
and additional mutations were found on parC at Ser80Arg or Glu84Lys. In Salmonella 
Choleraesuis from patients, gyrA mutations were found on codons Ser83Phe and 
Asp87Asn while mutation on parC was at Ser80Ile. The same mutations were found in 
Salmonella Typhimuirum from pigs. In serovar Choleraesuis from pigs the mutations were at 
Ser83Phe, Asp87Asn, or Asp87Gly coupled with parC mutations on Ser80Ile. 
Interestingly in both human and pig Salmonella Choleraesuis isolates resistant to CIP, the 
same point mutation was also found on acrR (efflux repressor gene) at Gln78Stp. The 
molecular typing survey has shown that Salmonella Typhimurium and Salmonella 
Choleraesuis spread from animals to humans in Taiwan (Chiu et al., 2004; Hsueh et al., 
2004). Other research supports the finding that double and triple mutant of Salmonella 
enterica serovar Choleraesusis circulates in several pig farms and that multiple mutations on 
topoisomerase genes confer resistance to fluoroqionolones in Taiwan (Huang et al., 2004). 
Clinical report on ciprofloxacin/ceftriaxone resistant Salmonella Choleraesuis infection in 
three patients admitted to Medical Centre in Southern Taiwan, reveals the same PFGE 
profile and point mutations on gyrA Ser83Phe, Asp87Asn and on parC Ser80Ile. All 
five isolates from patients also possess the blaCMY-2 gene. It was postulated that NAL resistant 
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Salmonella tend to cause higher death rate comparing to susceptible strains (Ko et al., 2005). 
Recently, one Salmonella Typhi isolate from a patient who returned from India was reported 
to have high MIC to ciprofloxacin (32g/ml) and subsequently two point mutations were 
discovered in gyrA Ser83Phe and Asp87Gly (Hassing et al., 2011). Recurrent infection 
with Salmonella enterica serovar Typhimurium DT104 occurred in a patient admitted to the 
hospital in Denmark. Initially the bacteria were susceptible to fluoroquinolones. The patient 
received low doses of ciprofloxacin and during the next year STDT104 emerged as 
quinolone resistant (MIC to CIP 0.190 g/ml), due to the single point mutation, on gyrA 
Ser83Phe (Kristiansen et al., 2003). In Salmonella one single point mutation on gyrA gene is 
sufficient to induce high level resistance to quinolones. Double mutations in gyrA or gyrA 
and other target genes for quinolones are not so common as in E. coli. However, if double 
mutations occur it usually leads to elevated or high resistance to FQ. High resistance to 
quinolones due to double and triple mutations is sometimes reported in patients who 
returned from Asia and/or Mediterranean countries. It is evident that Salmonella differs 
from continent to continent and depends on the medical treatment prescribed and overuse 
of antimicrobials in both human and veterinary medicine. In China it is also possible that 
stool specimens were sometimes collected after the onset of the disease and after the therapy 
had already been applied. This is due to easy access to the medication that is not under 
appropriate control of a physician (Cui et al., 2008). Salmonella is also the most frequent 
cause of traveller’s diarrhoea. Clinical isolates obtained in a five year study from the patients 
who returned from different countries (India, Mexico, Egypt, Peru, Kenya, Ivory Coast, 
Gambia, Senegal, Mali and Bolivia) were tested for antimicrobial resistance. In quinolone 
resistant strains a single amino acid substitution was found on Asp87Tyr and in one 
isolate a Ser83Tyr substitution was found. Amino acid substitution was not found on parC 
in this strain collection (Cabrera et al., 2004). Salmonella enterica serovar Typhi was found in 
the year 2006 and 2007, in two patients from Kuwait who returned from Bangladesh. In 
these isolates four point mutations were detected on QRDR, namely: Leu55Trp, 
Ser83Phe, Asp87Ala, Gln106Arg in gyrA gene. On parC gene mutations were found 
on Glu84Lys, Trp106Gly and Tyr128Asp (in bold are mutations reported for the first 
time in gyrA and parC genes) (Dimitrov et al., 2009). Reduced susceptibility in Salmonella 
enterica isolates from Finland was most frequent in patients who acquired infection abroad. 
Following mutations were reported on gyrA gene: Ser83Phe, Ser83Tyr, Asp87Asn, 
Gly or Tyr. Mutations on parC were not recorded in this survey (Hakanen et al., 1999; 
Hakanen et al., 2001).    
A research work from veterinary field is shortly presented here and clonal spread of 
Salmonella is described. Treatment of pigs infected with quinolone resistant Salmonella 
Typhimuirum DT104 with enrofloxacin cause higher shedding of resistant microorganism 
comparing to untreated control. This means that antibiotic treatment of pigs before 
slaughter will induce increased shedding and impose higher risk concerning food safety 
(Delsol et al., 2004). In chicken experiments it was shown that enrofloxacin treatment cause 
elevated MIC to ciprofloxacin (MIC 0.12-0.5 g/ml) if birds are infected with a susceptible 
strain of Salmonella enterica serovar Typhimurium DT104. In the same experiment a 
multidrug-resistant (MDR) derivate of the same strain appeared in the presence of 
enrofloxacin, exhibiting higher MIC to CIP (0.25-1g/ml). This isolate was cyclohexane 
tolerant, implicating the role of efflux pump in MDR strains (Randall et al., 2005). 
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Fig. 2. Multiple alignment of quinolone resistant Salmonella Enteritidis, isolated from stool, 
food and poultry in Serbia. Point mutations are presented in bold. This region encompasses 
codons 83 and 87. The reference strain is number 2 (Escherichia coli, ATCC 25922), in strain 
317526 the mutation was not found, implying another mechanism of resistance to 
quinolones 
Intercontinental spread of Salmonella Typhimurium definitive phage type 104 (STDT104) is 
well documented. Clonal spread of Salmonella Enteritidis PT1, resistant to quinolones (MIC 
for nalidixic acid >128 g/ml) also harbouring one unique point mutation on gyrA 
(Asp87Tyr) is reported in Ireland by Kilmartin et al. (2005). Salmonella Virchow has for 
many years been a common serotype in Israel. It is resistant to nalidixic acid and possesses 
the point mutation Asp87Tyr on gyrA gene (Solnik-Isaac, 2007). Since the year 2000, in the 
Netherlands and Germany Salmonella Java clonally spreads and is more prevalent compared 
to other serovars. This strain is resistant to chloramphenicol, sulphonamide, tetracycline, 
trimetoprim and often to kanamycin, neomycin and nalidixic acid. It is postulated that S. 
Java has emerged in the poultry industry due to the frequent use of antibiotics and because 
vaccination was implemented to eradicate Salmonella Enteritidis (van Pelt et al., 2003). 
Clonal spread of multiple resistant Salmonella Infantis (nalidixic acid, streptomycin, 
sulphonamide and tetracycline) is reported in Hungary where poultry isolates were linked 
to human's (Nógrády et al., 2007). Salmonella enterica serovar Haardt resistant to quinolones 
with elevated MIC to ciprofloxacin (MIC 0.25-2 g/ml) was found on chicken meat collected 
in various stores. Point mutation was detected on gyrA (Ser83Tyr). PFGE analysis implies 
clonal spread of NAL resistant S. Haardt in Korea (Lee et al., 2008). In Serbia S. Enteritidis 
isolated from humans, food and poultry was typed by Random Amplified Polymorphic 
DNA analysis (RAPD). In a collection of 60 strains, 9 were resistant to nalidixic acid. In these 
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strains 3 different single point mutations were found on gyrA, namely Asp87Asn in 6 
strains, Asp87Gly in 1 strain and Ser83Phe in one strain (Fig 2). For these isolates, MIC 
for NAL was 128-512 g/ml and MIC for CIP was 0.256-0,512 g/ml. In this strain collection 
multiple resistances was found in three isolates. Salmonella Enteritidis from one day old 
chicken was resistant to ampicillin (AMP), cephalothin (CFT), nalidixic acid (NAL) and 
tetracycline (TET). One isolate from stool was resistant to AMP, TET, trimetoprim-
sulfamethoxasole (SXT) and another isolate from stool exhibited resistance to AMP, TET, 
SXT and neomycin (NEO) (Kozoderović et al., 2011). There was an increase of Salmonella 
Enteritidis isolates in Serbia in 2005 and clonal spread was suspected. However, from 2005 
to 2008, the percentage of quinolone resistant Salmonella Enteritidis appeared to decrease 
from 9% to 1% in the Northern part of the country (Kozoderović et al., 2009). 
3. Point mutations in topoisomerase genes of E. coli  
Resistance to fluoroquinolones in E. coli has been extensively studied. Mutational 
polymorphism on topoisomerase genes in E. coli is frequent in clinical settings but also in 
commensal. First step mutations occur on gyrA gene, most frequently at codon 83, where 
substitution of Leucine for Serine is found (Chen et al., 2001; Conrad et al., 1996; Everett et 
al., 1996; Gales et al., 2000; Heisig and Tschorny, 1994; del Mar Tavio et al., 1999). The first 
report of double mutation in gyrA was provided by Heisig et al. (1993). The mutations in E. 
coli isolate 205096, highly resistant to FQ, were located on Ser83Leu and on Asp87Gly. 
Complete sequencing of the gene revealed additional mutation in less conserved region of 
the gyrA, at Asp678Glu. This mutation is not implicated in FQ resistance. Throughout the 
coding region, 52 silent mutations were also found. The authors stated that mutations at 83 
and 87 encompass part of the enzyme responsible for cleavage and sealing of the DNA. This 
is necessary to obtain negative supercoiling prior to strand separation. The quinolones 
prevent contact between DNA and enzyme thus aborting bacterial replication (Drlica & 
Zhao, 1997). In clinical E. coli isolated from urine samples of outpatients who did not receive 
FQ therapy, a novel mutation was found: Asp87Tyr. Concomitant mutation of Ser83Leu 
and Asp87Asn or Tyr, induced clinical resistance to CIP (MIC > 8 g/ml). The 
significance of the double mutant for high fluoroquinolone resistance is warranted (Vila et 
al., 1994). In clinical isolates of E. coli (MIC to CIP > 1 g/ml) mutations were found on gyrA 
and parC gene. Mutational polymorphism in this strain collection is briefly presented here. 
Mutant with MIC to CIP of < 1 g/ml have only one mutation at Ser83Leu. If MIC to CIP 
is from 8-128 g/ml, 3-4 mutations were found on gyrA (Ser83Leu or Asp87Tyr or Asn) 
and parC genes (Ser80Arg or Ile) and /or Glu84Lys or Val). In two isolates (1319 and 
1383) four mutations were found. The MIC to ciprofloxacin was 64 g/ml and 128 g/ml 
and mutations were arranged as follows: Ser83Leu, Asp87Asn, Ser80Ile and 
Glu84Val in isolate marked 1319, while a mutation's on Ser83Leu, Asp87Tyr, 
Ser80Ile and Glu84Lys were found in isolate marked 1318. This was the first report of 
parC mutation in E. coli (Vila et al., 1996). The role of parC mutations in highly quinolone 
resistant E. coli was studied by Kumagai et al., 1996. In the QRDR of the parC gene three 
missense mutations on codons Gly78, Ser80 and Glu84 were described corresponding to the 
gyrA mutations on codons Ser83, Gly81 and Ap87. In this research the importance of 
mutations in topoisomerase IV, in building resistance to FQ in E. coli was emphasized. The  
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role of mutations on FQ resistance was also studied by Heisig (1996). In parC mutant a 
reduction in MIC to CIP was recorded after introduction of the wild type gene to mutants. If 
parC1-80 allele (a single mutant) is introduced into isolates that have two point mutations on 
parC, an increase of susceptibility is noted, while introduction of resistant parC allele to gyrA 
mutants will induce an increase of MIC to CIP. Mutation of parC in E. coli having two point 
mutations on gyrA is a prerequisite for high FQ resistance phenotype. The mutations 
induced by FQ occur in stepwise manner and the primary target for CIP is Gyrase (Bagel et 
al., 1999). The level of quinolone/fluoroquinolone resistance correlates well with the type 
and number of mutations on topoisomerase genes. The CLSI breakpoint for FQ is obtained if 
double mutations on gyrA are combined with single or double parC mutant (Morgan-Linnell 
and Zechiedrich 2007; Sáenz et al., 2001). If a mutation on parC occurs in a single gyrA 
mutant, second mutation on gyrA is selected (Morgan-Linnell and Zechiedrich 2007). 
Therefore gyrA mutation is indispensable for clinical resistance to quinolones and it mostly 
occurs before parC mutations, especially in clinical isolates. Single parC mutation does not 
induce resistance to FQ (Bagel et al., 1999). If E. coli is exposed to quinolones, a stepwise 
mutagenesis may lead to development of a new feature that is beneficial for these bacteria. 
Usually selection pressure is imposed by application of various quinolones or 
fluroquinolones in agriculture. In such scenario a single step mutant can become 
predominate in the population. This will contribute to developing multiple mutations and 
high resistance to fluoroquinolones in clinical isolates after therapy has been introduced 
(Piddock et al., 1996). Infection with Fluoroquinolone resistant E. coli acquired in hospitals is 
of special concern. The resistant strains usually evolve independently and the therapy may 
be difficult to introduce. In the mid 1990, the percent of fluoroquinolone resistant E. coli 
increased in many countries. Lehn et al. (1996) described resistotype and mutations on gyrA 
in a collection of 19 E. coli resistant to CIP in hospital settings in Munich, Germany. The 
majority of isolates were multiple resistant to the following antibiotics: nalidixic acid, 
ciprofloxacin, norfloxacin, aminoglycosides, co-trimoxazole, ampicillin, ampicillin and 
sulbactam and piperacillin. Most isolates obtained for the study were from Urology 
Department, from Gynecology, Surgery and Internal Medicine. PFGE typing implicates 
diversity of the strains but resistotype was quite similar. Also, the mutations on 
topisomerase were documented on Ser83Leu, Asp87Asn in 16 strains. In two strains 
Asp was mutated to Gly. Resistance of E. coli to FQ is equally reported in developed and 
developing countries. At highest risk are patients that are hospitalized and treated with 
antibiotic. Several studies have dealt with various aspects of infection with E. coli in 
hospitals and outpatient clinics. In a study from Taiwan, a total of 1203 isolates of E. coli 
from 44 hospitals were tested on antimicrobial susceptibility and it was found that 11.3% 
isolates were resistant to FQ. Decreased susceptibility to CIP was found in 21.7% isolates. A 
single point mutation was found on gyrA among FQ resistant and isolates with reduced 
susceptibility. The authors postulated that such single mutation is a prerequisite for 
resistance development. In FQ highly resistant strains (MIC >32µg/ml) three or four point 
mutations were found in QRDR of the gyrA, and parC. These included substitution at 
Ser83Leu, Asp87Asn, coupled also with Ser80Ile (9 isolates) or Ser80Arg (one 
isolate), Ala81Pro (one isolate) and Glu84Gly or Lys (one isolate). The survey in Taiwan 
reveals high risk on FQ resistance in clinical E. coli isolates. It was noted that patients 
diagnosed with cancer were predisposed to infection with resistant E. coli. Nalidixic acid 
and pipemidic acid are still in medical practice and these practices pose a risk for higher FQ 
resistance in Taiwan (McDonald et al., 2001). Two or more mutation on topisomerase II and  
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IV were found in a hospital strain collection in South Korea. In fact, the number of acquired 
mutations was proportional to MIC for ciprofloxacin. The CIP resistant isolates were 
divided into 4 groups depending of the number of mutations in topoisomerase genes. It was 
concluded that second step mutant will induce double mutation on parC and that double 
parC mutant are highly resistant to fluoroquinolones. All of the parE mutations were outside 
the QRDR. Three novel parE mutations were reported on Leu445Ile, Ser458Pro and 
Ser458Trp. These single mutations on parE significantly increased MIC to CIP, norfloxacin 
and gatifloxacin. In this strain collection three to four mutations on topisomerase II and IV 
were common. Mutations on gyrB were not found. Combination of double mutations on 
parC or single parC and parE mutation increases MIC of ciprofloxacin (Chan Moon et al., 
2010). Mutational polymorphism was found in clinical isolates of E. coli in New Delhi, India, 
revealing that a number of isolates possess several mutation on topisomerase genes and that 
mutation on parE was prominent since 44.4% of isolates are mutated on parE, outside of 
QRDR. The substitutions found on parE were Ser458Ala and Glu460Asp. Mutations on 
both genes (parC and parE) being the secondary target for FQ contributed to higher MIC 
>0.25 µg/ml for ciprofloxacin (Bansal and Tandon, 2011). Asian Network for Surveillance of 
Resistant Pathogens provided 68 E. coli isolates resistant to FQ, to carry out a research on 
geographic distribution of mutational polymorphism. Clonal spread was not evident. 
Continentally distributed isolates possessed a variety of mutation in topoisomerase genes 
but those with three or more mutations were increasingly resistant to CIP. This high 
increase was attributed also to the mutation of the parE gene (Uchida et al., 2010). E. coli 
isolates from healthy patients in Teaching Hospital and Microbiology Department at the 
University in Ghana were studied with respect to FQ resistance. About 50 to 90% of faecal 
isolates from healthy individuals were multiple resistant to the following antimicrobial 
agents: ampicillin, streptomycin, tetracycline, sulphonamides and trimethoprim. The 
obtained results revealed that in the year 2008, 18.2% of isolates were resistant to NAL and 
9.9% were resistant to FQ. In resistant isolates the most frequent substitution was 
Ser80Leu often combined with Asp87Asn in gyrA and on parC the most frequent 
substitution was at Ser80Ile. The mutation in topoisomerase that was found was 
attributed to old and recently introduced drugs in clinical practice in Ghana. Presence of 
multiple resistances in commensal microflora in patients is noted and the prudent use of 
fluoroquinolones is warranted (Namboodiri et al., 2011). Bacteria change phenotype, 
depending on the selection pressure. This has been shown in research on resistance 
mechanisms in laboratory mutants and clinical isolates. We have learned that careful use of 
antibiotics is essential and must be under control or it will be impossible to cope with the 
infections acquired in hospitals and the environments from which subsequent transfer of 
resistant bacteria is common. Topoisomerase mutators can have prohibitive fitness cost or 
might have selection advantage. 
E. coli with single point mutation on gyrA was found in veterinary isolates and it was 
suggested that the digestive tract of animals can be a reservoir of low level resistance to 
quinolones. If such bacteria find their way to humans through the food chain, clinical 
resistance will occur in patients that needs therapy (Everett et al., 1996). A heterogenic 
population of quinolone resistant E. coli collected from poultry, poultry farmers and poultry 
slaughterers was described by van den Bogaard et al. (2001). Only in few isolates a link 
between poultry and poultry farmers was noted, implying that E. coli from animals could 
also infect people. Mutations on topoisomerase genes in E. coli isolated from faeces of 
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healthy chickens in six broiler and 4 breeder farms in Korea was described by Lee et al. 
(2005). All isolates resistant to ciprofloxacin and enrofloxacin exhibited mutations on 
Ser83Leu. Many isolates also harbour second mutation on Asp87Asn, Ala, Gly, His or 
Tyr. In this strain collection, mutations were also found on parC, the most prevalent being 
Ser80Arg, Ile, Phe and Gly and in some isolates, mutation were found on Glu84Lys, 
Ile and Tyr. The MIC breakpoint to CIP and ENR was >3 g/ml and 2 g/ml respectfully. 
The isolates with two mutations distributed on gyrA and parC had elevated MIC to 
ciprofloxacin (0.5-3 g/ml) while MIC to ENR was 1 to 32 g/ml. Isolates presented by 
greater MIC than clinical breakpoint had two mutations on gyrA (at codons 83 and 87) 
with or without substitution on parC . Khan et al. (2005) found out that the poultry litter 
collected from poultry and turkey farms in the Arkansas, USA becomes an important 
source of quinolone resistant E. coli. In isolates resistant to CIP (> 2 g/ml) two point 
mutations were found at Ser83Leu and Asp87Asn. Single point mutation in MIC < 2 
g/ml was found on Ser83Leu. Beef, pork and poultry are considered as the main 
reservoir of quinolone resistant E. coli, Salmonella and Campylobacter (Mayrhofer et al., 
2004). Nine E. coli isolates from wild birds that died from septicemia were tested on 
quinolone resistance. It was found that all the strains had one mutation on gyrA gene at 
Ser80Leu. Mutations on other target genes (gyrB, parC and parE) were not found 
(Jiménez Gómez et al., 2004). The high incidence of quinolone resistant E .coli from 
nosocomial and community acquired infections is linked to a high incidence of FQ 
resistant E. coli in poultry and pigs. The clear connection between human and poultry 
isolates was not, however, found in Spain but it was postulated that the infection of 
humans occurs via contaminated food of animal origin Garau et al. (1999). Indeed, it is 
difficult to explicitly claim that the link exists between poultry related food and humans 
but the similarities are present in resistant isolates, compared to susceptible strains. The 
general statement is that the misuse of quinolones largely contributes to the spread of 
resistant bacteria through the food chain (Johnson et al., 2006).  
It is difficult to explain how FQ resistance evolves in E. coli and how it spreads in clinical 
settings. It seems that E. coli mutates to a higher extent compared to Salmonellae and is 
capable of accumulating several point mutations at the same time or in a stepwise manner. 
Since the FQ resistant phenotype arises exclusively after de novo mutations (Mooij et al., 
2005) it seems that microorganisms harbouring one single amino acid substitution are prone 
to mutate and more easily survive in the environment. High mutation rates could also lead 
to the development of deleterious mutations. Strong mutators therefore do not always have 
an evolutionary advantage. If the high mutation rate of E. coli will not favour its survival, 
then the only way to explain the presence of resistant population in a certain zone is 
exposure of bacteria to antimicrobials. E. coli tends not to spread clonally in hospital settings 
(Lautenbach et al., 2006) and also in the environment (Khan et al., 2005). It is not clear 
whether isolates with multiple mutations on target genes have some evolutionary 
advantage so it appears that multiple mutations have low fitness cost. If such mutations are 
accumulated, compensatory mutations will support growth. On the contrary there are 
examples where multiple mutations have actually increased bacterial fitness. This also takes 
place in the absence of antibiotics. Mutations on regulatory genes have the highest influence 
on bacteria fitness, since those genes regulate transcription and also efflux mechanisms 
(Marcusson et al., 2009). 
www.intechopen.com
Mutational Polymorphism in the Bacterial  
Topoisomerase Genes Driven by Treatment with Quinolones 
 
197 
4. Point mutations in topoisomerase genes in Campylobacter spp 
Infections caused by Campylobacter usually have a very silent course in animals (Stojanov et 
al., 2004). However, Campylobacteriosis is the most frequent reason for gastroenteritis in 
humans. If food producing animals (pigs and poultry) are treated with enrofloxacin (a 
fluoroquinolone antibiotic) Campylobacter develops resistance that lasts well beyond 
withdrawal of the therapy (Delsol et al., 2004; Griggs et al., 2005; Luo et al., 2005). 
Subsequently food can be contaminated during processing, increasing the possibility of 
transmission to humans. Ciprofloxacin resistant Campylobacter emerged on the European 
continent in the early 1990 and this coincides with the agricultural practice to treat animals 
with enrofloxacin. At that time in the United Kingdom human Campylobacter infections were 
reported most frequently in travellers returned from abroad, while ciprofloxacin resistant 
Campylobacter was found in poultry carcasses imported from Europe (Gaunt and Piddock, 
1996). In Northern Ireland, ciprofloxacin resistance of Campylobacter rose in 1998. This was 
attributed to dietary habits of the consumers in the UK. Chicken and pork meat 
consumption increased because of Bovine spongioform encephalopathy. Subsequently the 
import of poultry meat from the European countries might have contributed to the spread of 
fluoroquinolone resistance (Moore et al., 2001). The National Antimicrobial Resistance 
Monitoring Program (NARMS) was conducted from 1997 to 2001 to identify susceptibility of 
Campylobacter for the following antimicrobials: chloramphenicol, ciprofloxacin, clindamycin, 
erythromycin, nalidixic acid, tetracycline, azithromycin and gentamycin. Isolates were 
collected based on a questionnaire that included: history of recent illness, exposure to 
animals, food consumption or travelling. Retail chicken meat products from domestic brand 
were also included in the study. An increase of ciprofloxacin resistant Campylobacter from 
13% in 1997 to 21% in 2001 was found. Foreign travel was identified as a risk of FQ resistant 
Campylobacter infection in humans but also consumption of chicken meat. The increase of 
CIP resistant Campylobacter coincides with the increasing use of fluoroquinolones in human 
medicine and livestock industry in the USA (Gupta et al., 2004). Infection with CIP resistant 
Campylobacter in a Minnesota community was related to travels abroad and seasonal peaks 
were identified. Overall increase in Campylobacter isolates resistant to CIP from the year 1996 
to 1998 was attributed also to domestically acquired infections. Poultry meat and products 
were identified as a source of infection and a genetic correlation between human and 
poultry isolates was determined (Smith et al., 1999). However, Campylobacter is genetically 
quite diverse and clear links between food of animal origin and humans is not easily 
confirmed. In fact, diverse Campylobacter isolates were noted on a single swine farms and 
slaughter plant in the USA (Thakur and Gebreyes, 2005). Similar results were obtained in 
Senegal in a two-year period, applying multilocus sequence approach in Campylobacter 
isolated on chicken carcasses. Allelic profiles in Campylobacter jejuni (Kinana et al., 2006) and 
Campylobacter coli (Kinana et al., 2007a) imply genetic differences in this strain collection. 
The link between genotype and quinolone resistance was not found with certainty in their 
research. Even for the isolates of the same sequence type, different silent mutations were 
found on gyrA gene. In the research conducted in France an increase in FQ resistant 
Campylobacter was recorded for the period 1986 to 2004. The FQ resistance pattern was 
similar between human, pig and poultry isolates. In C. coli the overall resistance rate was 
higher comparing to C. jejuni. In pigs, C. coli predominated over C. jejuni and it was more 
frequently resistant to CIP. The higher rate of C. coli isolation in pigs and chickens is not 
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explained. The FQ resistance pattern was similar in C. jejuni isolates found in humans and 
broilers. Resistance decreased to lesser extend in human C. jejuni comparing to chicken. This 
is explained in part by restrictive use of antimicrobials as food additives in livestock 
industry and may also be related to various routes of infection in humans and therapeutic 
practice in human medicine (Gallay et al., 2007). Overall, it has been shown that people are 
infected from food of animal origin and that intensive use of quinolones and 
fluoroquinolones in livestock industry undoubtedly contributes to the development of 
resistance. Molecular typing of the Campylobacter species revealed quite diverse genetic 
backgrounds and apparent clonal distribution was not identified. The prudent use of FQ 
antibiotics is necessary to build up safe environment and safe food production. 
The ability of Campylobacter to acquire resistance to quinolones/fluoroquinolones is rather 
impressive. The most frequent missense mutation in gyrA gene is Thr86Ile. The codon 86 
in Campylobacter corresponds to gyrA codon 83 in E. coli and Salmonella (Beckmann et al., 
2004; Griggs et al., 2005; Hakanen et al., 2002; Sonnevend et al., 2006; Wang et al., 1993, 
Zirnstein et al., 2000). This single point mutation confers resistance to ciprofloxacin and MIC 
is > 32µg/ml. Less frequent mutation in QRDR of the gyrA in Campylobacter are 
Asp90Asn, Thr86Lys, Thr86Ala, Thr86Val and Asp90Tyr. Double mutant are 
found on Thr86Ile-Pro104Ser and Thr86Ile-Asp90Asn (rev by Payot et al., 2006). 
Campylobacter isolates originating from broilers, turkeys and humans resistant and sensitive 
to NAL were examined for mutations within QRDR. In 135 resistant strains the most 
frequent mutation was Thr86Ile and thereafter mutations were found on Thr86Ala, 
Asp90Asn and Pro104Ser. It is not known whether mutation on Pro104Ser influence 
the resistance to FQ. In susceptible isolates as well as in resistant strains, silent mutations 
were on codons Gly78, His 81, Gly110 and Ser119. Genetic variation is therefore common in 
C. jejuni isolated from chickens, turkeys and humans (Beckman et al., 2004). Mutations on 
gyrB gene are rare in Campylobacter resistant to NAL and CIP. Piddock et al. (2003) reported 
silent mutation on gyrB in few isolates of Campylobacter species. In clinical isolates of C. coli, 
C. jejuni, C. lari and C. fetus obtained from UK, Germany and  the Netherlands, from the 
period 1990 to 1995, the most frequent mutation on gyrA was Thr86Ile. In one isolate 
mutation on Asp90Asn was found and one isolate was double mutant (Thr86Ile-
Pro104Ser). Silent mutations were found on gyrA in C. jejuni suggesting genetic and 
epidemiological differences between the isolates. In Senegal silent mutation of gyrB was 
found in a collection of isolates from chicken carcasses. These silent mutations were 
identified from codons 371-540. Besides silent mutations the dominant transition on gyrA 
was Thr86Ile and six isolates mutated on Thr86Ala. The amino acid substitution 
Thr86Ala was found also in two chicken isolates susceptible to CIP and MIC to NAL was 
16 µg/ml. In 17 isolates mutations were found at Asn203Ser, downstream gyrA and in 3 
isolates mutations were found also at Ala206Thr. The parC gene could not be amplified 
(Kinana et al., 2007b). In a strain collection of CIP resistant C. coli, isolated from humans, 
food and animals in Italy, a novel mutation at codon 86 was described. This was a double 
nucleotide substitution at ACT  GTT changing Thr86Val in three C. coli isolates. This 
type of transition did not induce additional increase of MIC to CIP. In C. coli different gyrA 
alleles were found, but the mutations were silent, pointing only to the genetic diversity of 
the unrelated isolates from Italy. Mutation Thr86Ile on gyrA was associated with high 
MIC to ciprofloxacin (MIC >32 µg/ml) (Carattoli et al., 2002). In six clinical isolates from the 
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research of McIver et al. (2004) mutation was identified on Thr86Ile, but in laboratory 
derived mutants three non-synonymous substitution were identified at Asp90Asn, 
Asp85Tyr and Thr86Ala. This was a first report of double mutation Asp85Tyr-
Thr86Ile in Campylobacter after in vitro exposition to sub-inhibitory concentration of 
ciprofloxacin. Silent mutations apparently do not improve in vivo fitness cost of the resistant 
Campylobacter nor its colonization ability, which is preserved even in the absence of 
antibiotics. Its viability is solely due to single point mutation in gyrA gene. This is probably 
the reason why FQ resistant Campylobacter persist in farm animals over a long period and 
because once contaminated with such bacteria the farm presents a hazard in food 
production (Luo et al., 2005). Double gyrA mutant is reported from Thailand in C. coli 
isolated from pigs. Mutations were found in gyrA at Thr86Ile and Gly119Ser and in 
three isolates also amino acid substitution on gyrB were Lys382Gln or Arg. These 
additional mutations did not increase MIC to CIP or NAL, so its possible role in resistance 
mechanism needs to be determined in the future (Ekkapobyotin et al., 2008). Double 
mutations on gyrA (Thr86Ile) and parC (Arg139Gln) were found in clinical isolates of C. 
jejuni in patient that were treated with fluoroquinolones because of profound diarrhea. The 
mutation on parC gene is rare and is coupled with amino acid transition on gyrA. The 
influence of parC mutation on MIC for CIP is not clear (Gibreel et al., 1998).  
Implications of gene mutations to NAL resistance phenotype was studied by Jesse et al. (2006) 
and an observation was made that single point mutation on Thr86Ala confers the resistance 
to NAL but not to CIP. Most isolates from their strain collection, obtained from chicken 
carcasses and cattle faeces, also possessed one or more silent mutations in the gyrA gene. Silent 
mutations, double mutant in gyrA gene and also mutations outside of the QRDR/gyrA, 
usually do not change the MIC significantly but contribute in allelic diversity and in that 
respect can be used as a typing tool or in research on correlation between strains found in 
humans and animals. Multilocus sequence fla typing successfully discriminated C. jejuni and 
C. coli in the strain collection from the Institute of Veterinary Bacteriology  at the University of 
Bern, Switzerland. This method can be used in epidemiology research and in studying 
phylogenetic relation and divergence in large collection of isolates over a longer period of time 
(Korezak et al., 2009). The fla Restriction Fragment Length Polymorphism (RFLP) is a good 
alternative in research on genetic diversity of Campylobacter spp. (Keller & Perreten, 2006, 
Sonnevend et al., 2006). Campylobacter fetus subsp. fetus (wild type isolate and laboratory 
obtained mutants) is intrinsically resistant to NAL and resistance to CIP is obtained from the 
single transition of Asp91Tyr. The MIC to CIP does not exceed 8µg/ml for laboratory 
mutants. For clinical isolates the obtained MIC was 16 µg/ml (Taylor & Chau, 1997). 
Campylobacter fetus was isolated in two immunodeficient patients. The clinical symptoms of 
gastrointestinal disorder relapsed after therapy with fluoroquinolones. In re-isolated 
Campylobacter a mutation on gyrA gene was found at Asp87Thr. The authors stated that in 
immunodeficient patients it is very important to control resistance status before, during and 
after the treatment to enable successful therapy and prevent a failure (Meier et al., 1998). 
Campylobacter hyointestinalis subsp. hyointestinalis, isolated from reindeer and bovine fecal 
samples from the northern Finland were tested on antimicrobial resistance and gyrA mutations 
obtained in vitro. C. hyointsetinalis is intrinsically resistant to NAL and susceptible to CIP. In 
isolate naturally resistant to NAL an amino acid substitution Thr86Ile was found. The same 
transition (Thr86Ile) was recorded from in vitro obtained mutants (grown in a gradually 
increasing concentration of ciprofloxacin) with MIC of >64 µg/ml. In the strains that exhibit 
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MIC to CIP <32 µg/ml, gyrA was not mutated implicating other mechanism of inherent 
resistance, was not mutated implicating other mechanism of inherent resistance (Laatu et al., 
2005).  
Mutational polymorphism in QRDR region of the gyrA gene in Campylobacter species is not 
exclusively driven by antimicrobial therapy in livestock industry but also occurs after 
therapy of patients. To decrease spreading of resistant bacteria in agriculture, since 2005 
fluoroquinolones have been banned in poultry and swine industry in the USA. Other 
antimicrobial agents must be used to treat E. coli infections in pigs and poultry in North 
America. The most important approach to combat resistance in bacteria is therefore good 
management, food safety and good cooking practice. It is hard to expect that the problems 
of antibiotic resistance will be entirely resolved since bacteria find ways to survive under 
selective pressure created by man but also in their own environment and communities. 
Permanent monitoring of antimicrobial resistance and resistance mechanism is essential and 
must be carried out in each country under national programs and preferable supported by 
international projects. Point mutations in a single gene of topoisomerase enzymes are a good 
example of the smart game that bacteria play to survive and spread in nature.  
5. Conclusion 
Antibiotic resistance monitoring is compulsory in developed countries but is also conducted at 
similar level in developing countries. Since resistance development is attributed to the use of 
antimicrobial agents in clinical therapy and livestock industry, medical and veterinary sector is 
equally involved in resistance monitoring. We have learned that resistance to “old” antibiotics 
can lead to bacteria that  inherit more than one mechanism of resistance, that could develop 
MDR phenotype and that the new feature is sometimes fitness cost effective. Mutations on 
target genes selected in vitro do not necessarily resemble the nature of mutational frequency in 
vivo, but with certainty enable scientist to understand how resistance develops and what the 
risk is of antibiotic use. Epidemiologists have put much effort to explain the spread of resistant 
bacteria and to find their origin. They have tried to explain their intercontinental appearance. 
Vehicles for the transmission are numerous and it is usually impossible to find the exact path 
of their spread in humans and also animals. By utilizing molecular biology methods, clones 
and links that are attributed to their transfer from one setting to another can be identified. 
Mutations on topoisomerase genes determine the genetic background of the bacteria and in 
some instances increase the success of their survival in nature.  
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